Hopital Huriez

The trials here

What the 21 trials at this site are about, from their registry records.

Conditions

• Childhood cancers2 trials
• Colorectal cancer2 trials
• Gastric and oesophageal cancer2 trials
• Multiple myeloma2 trials
• Systemic sclerosis (scleroderma)2 trials
• Acute myeloid leukaemia1 trial
• Chronic spontaneous urticaria1 trial
• Giant cell arteritis1 trial
• Liver and biliary tract cancer1 trial
• Lupus (SLE)1 trial
• Mantle cell lymphoma1 trial
• Neuroendocrine tumours1 trial
• and 4 more

Phase

• Phase 311 trials
• Phase 29 trials
• Phase 1/21 trial

Status

• Active, not recruiting7 trials
• Completed7 trials
• Recruiting6 trials
• Not yet recruiting1 trial

Lead sponsor

• Centre Hospitalier Universitaire De Nantes2 trials
• Novartis Pharmaceuticals2 trials
• University Hospital, Rouen2 trials
• Arcus Biosciences, Inc.1 trial
• argenx1 trial
• and 13 more

Running trials

• Active, not recruiting

  Prospective multicenter randomized controlled double-blind label study of the prophylaxis of recurrent pouchitis after fecal microbiota transplant in UC with ileo-anal anastomosis.

  NCT03524352· Phase 3· Centre Hospitalier Universitaire De Nantes· Source

• Not yet recruiting

  A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

  2025-521090-14-00· Phase 2· Assistance Publique Hopitaux De Paris· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

  NCT06655155· Phase 2· argenx· Source

• Active, not recruiting

  A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines

  2023-505739-12-01· Phase 3· Novartis Pharma AG· Source

• Recruiting

  Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· Phase 3· AstraZeneca· Source

• Recruiting

  Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy

  NCT06107920· Phase 3· University Hospital, Rouen· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma

  2023-503206-37-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Active, not recruiting

  A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

  NCT05985915· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busulfan versus fludarabine/busulfan) in adults with acute myeloid leukemia and eligible to allogeneic stem cell transplantation: a SFGM-TC study

  2022-502019-12-00· Phase 3· Centre Hospitalier Universitaire De Nantes· Source

• Active, not recruiting

  MSI/dMMR tumors in perioperative setting

  NCT04795661· Phase 2· Centre Leon Berard· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

  NCT05050136· Phase 2· Mirum Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma

  NCT04561492· Phase 2· Nantes University Hospital· Source

• Recruiting

  Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

  NCT04325425· Phase 2· Centre Hospitalier Universitaire Dijon· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer2 recruiting
• Acute myeloid leukaemia1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple myeloma1 recruiting
• Neuroendocrine tumours1 recruiting
• Pancreatic cancer1 recruiting

Closed trials

• Not yet recruiting

  Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis

  NCT05651880· Phase 3· University Hospital, Rouen· Source

• Active, not recruiting

  A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

  NCT06246643· Phase 2· Bayer· Source

• Completed

  A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

  NCT04781543· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

  NCT05568095· Phase 3· Arcus Biosciences, Inc.· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

  NCT04895696· Phase 2· Beeline Medicines Corporation· Source

• Completed

  Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

  NCT04930094· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  ROLLOVER STUDY FOR TAZEMETOSTAT

  NCT02875548· Phase 1/2· Epizyme Inc.· Source